These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 22548227)
41. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Ocak S; Gorur S; Hakverdi S; Celik S; Erdogan S Basic Clin Pharmacol Toxicol; 2007 May; 100(5):328-33. PubMed ID: 17448119 [TBL] [Abstract][Full Text] [Related]
42. Contrast associated nephropathy in the elderly. Carrillo-Alvira F; Rivera-Bermúdez CG; Jiménez-Velázquez IZ; Ramos-Romey C; González-Concepción JJ Bol Asoc Med P R; 2008; 100(3):25-7. PubMed ID: 19227712 [TBL] [Abstract][Full Text] [Related]
43. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Meschi M; Detrenis S; Musini S; Strada E; Savazzi G Crit Care Med; 2006 Aug; 34(8):2060-8. PubMed ID: 16763513 [TBL] [Abstract][Full Text] [Related]
44. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question. Mehran R; Caixeta A Rev Esp Cardiol; 2010 Jan; 63(1):9-11. PubMed ID: 20089220 [No Abstract] [Full Text] [Related]
51. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Shalansky SJ; Pate GE; Levin A; Webb JG Heart; 2005 Aug; 91(8):997-9. PubMed ID: 16020580 [TBL] [Abstract][Full Text] [Related]
52. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. Fishbane S; Durham JH; Marzo K; Rudnick M J Am Soc Nephrol; 2004 Feb; 15(2):251-60. PubMed ID: 14747371 [TBL] [Abstract][Full Text] [Related]
53. Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats. Yen HW; Lee HC; Lai WT; Sheu SH Arch Med Res; 2007 Apr; 38(3):291-6. PubMed ID: 17350478 [TBL] [Abstract][Full Text] [Related]
54. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012 [TBL] [Abstract][Full Text] [Related]
56. Tubulointerstitial injury: early or late event in the pathogenesis of hypertensive nephropathy? Tylicki L; Rutkowki B Kidney Int; 2004 May; 65(5):1971-2; author reply 1972. PubMed ID: 15086947 [No Abstract] [Full Text] [Related]
57. The role of oxidatively modified lipoproteins in lipid nephropathy. Gröne HJ; Walli AK; Gröne EF Contrib Nephrol; 1997; 120():160-75. PubMed ID: 9257059 [No Abstract] [Full Text] [Related]
58. The hemolytic uremic syndrome as a complication of adriamycin nephropathy. Viero RM; Soares VA Ren Fail; 1998 Jul; 20(4):565-71. PubMed ID: 9713874 [TBL] [Abstract][Full Text] [Related]
59. Nephrotoxicity of iodixanol versus iopamidol inpatients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Solomon R Am Heart J; 2010 Feb; 159(2):e7; author reply e9. PubMed ID: 20152210 [No Abstract] [Full Text] [Related]
60. Re: Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. Funaki B J Vasc Interv Radiol; 2001 Jul; 12(7):894. PubMed ID: 11435549 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]